AI assistant
Laurus Labs Limited — Call Transcript 2024
Oct 17, 2024
62639_rns_2024-10-17_3896d4a0-bb61-46b9-96e5-d937622eae26.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [191 x 81] intentionally omitted <==
October 17, 2024
To To The Corporate Relations Department The Listing Department BSE Limited National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Code: 540222 Code: LAURUSLABS
Dear Sir / Madam,
Sub: Q2 & H1 FY25 Earnings Conference Call Invite
Please find enclosed the Q2 & H1 FY25 Earnings conference call invite for the call scheduled on October 24, 2024 at 04.30 PM (IST).
This is for your information and records.
Yours faithfully,
For Laurus Labs Limited
VENKATESWAR Digitally signed by VENKATESWAR REDDY REDDY GOGIREDDY GOGIREDDY Date: 2024.10.17 11:42:23 +05'30'
G. Venkateswar Reddy
Company Secretary & Compliance Officer
Encl: A/a
==> picture [452 x 76] intentionally omitted <==
==> picture [218 x 93] intentionally omitted <==
Laurus Labs Q2 & H1 FY25 Results Conference Call
Hyderabad, October 17, 2024: Laurus Labs Ltd (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028), a leading research and development driven pharmaceutical and biotech company will organize a conference call to discuss Q2 & H1 FY25 results followed by an interactive Q&A. The call will be hosted by Antique Stock Broking. Dial In and other details given below
| Date and Time | October 24, 2024 - 4:30 pm IST |
|---|---|
| Conference dial-in | |
| Primary Number | +91 22 6280 1342 |
| Secondary Number | +91 22 7115 8243_Available all over India_ |
| Singapore | 800101 2045 |
| Hong Kong | 800964 448 |
| Japan | 00531161110 |
| USA | 1 866 746 2133 |
| UK | 0 808 101 1573 |
| Diamond Pass | Event Link |
END
| Investors Relations Vivek Kumar T +91 40 3980 4366 [email protected] |
Media Relations Karthik C T +91 40 3980 4380 [email protected] |
|---|---|
Corporate Office
2[nd] Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India T +91 40 6659 4333, 3980 4333, 2342 0500/501 F +91 40 6659 4320 / 3980 4320
Registered Office
Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India CIN : L24239AP2005PLC047518, T +91 891 682 1101, 1102, F +91 891 682 1103, E [email protected], W lauruslabs.com
==> picture [169 x 72] intentionally omitted <==
About Laurus Labs
As a research-driven pharmaceutical manufacturing organization, Laurus Labs has been developing and assisting its client organizations to succeed in innovative medicines that globally enhance the health outcomes for patients. Since our inception in 2005, we have been developing and manufacturing APIs and Intermediates. We have global leadership position in APIs, including Anti-retroviral, Oncology, Cardiovascular, and Gastro therapeutics. Our position was strengthened by our backward-integration and strong regulatory compliance across all operations. We emerged as one of the most trusted CMO and Contract Development and Manufacturing Organization (CDMO) service provider to Global Innovators from drug development phase to commercial manufacturing. Laurus employs 6700+ people, including around 1,100+ scientists across 14 manufacturing sites approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UKMHRA, EMA, TGA etc. During FY2024 Laurus generated ₹ 5,041 crore in annual revenue and is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange) in India. Laurus' proactive stance to conduct business with utmost Transparency, Integrity and Respect for environment & communities have earned it a place in Governance benchmark, consistently Certified Great Place to Work and Rated “BBB” by leading MSCI ESG Ratings. Corporate Identification No: L24239AP2005PLC047518.
For more information visit www.lauruslabs.com
Follow @ Laurus Labs on LinkedIn | Twitter | Facebook | Instagram
2